efgartigimod PH20 subcutaneous
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for efgartigimod PH20 subcutaneous, covering 2024-10-31 to 2024-10-31. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia [Phase 3]